An Endogenous Reactive Oxygen Species (ROS)-Activated Histone Deacetylase Inhibitor Prodrug for Cancer Chemotherapy
作者:Somnath D. Bhagat、Usha Singh、Ram Kumar Mishra、Aasheesh Srivastava
DOI:10.1002/cmdc.201800367
日期:2018.10.8
hydroxamic acid (SAHA, vorinostat) is a potent small‐molecule pan‐inhibitor of histone deacetylases (HDACs) approved for treatment of cutaneous T‐cell lymphoma (CTCL). However, SAHA exhibits poor selectivity for cancer cells over noncancer cells. With an aim to improving its selectivity for cancer cells, we generated a novel SAHA prodrug (SAHA‐OBP) that is activated in the presence of hydrogen peroxide, a
Suberoylanilide异羟肟酸(SAHA,vorinostat)是一种有效的小分子组蛋白脱乙酰酶泛抑制剂(HDACs),已批准用于治疗皮肤T细胞淋巴瘤(CTCL)。然而,与非癌细胞相比,SAHA对癌细胞显示出较差的选择性。为了提高其对癌细胞的选择性,我们生成了一种新型的SAHA前药(SAHA-OBP),该药物在过氧化氢的存在下被激活,过氧化氢是一种已知在癌细胞中过表达的活性氧(ROS)。癌细胞中较高的内源ROS含量会触发快速去除4-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)苄基羰基(OBP)帽以释放活性SAHA。SAHA-OBP前药对多种癌细胞系(例如HeLa,MCF-7,MDA-MB-231和B16-F10)表现出选择性活性,同时对非癌细胞保持良性。SAHA-OBP释放的SAHA对癌细胞的下游作用是诱导凋亡。还发现SAHA-OBP对多细胞肿瘤球体(MCTS)有效